RIGEL PHARMACEUTICALS Business Summary

Rigel Pharmaceuticals Inc. (RIGL) is a commercial-stage biotechnology company that generates revenue primarily through the domestic sale of its proprietary small-molecule targeted therapies and through international licensing and collaboration agreements. The company’s revenue model is bifurcated into net product sales—driven by its flagship SYK inhibitor TAVALISSE for immune thrombocytopenia, the IDH1 inhibitor REZLIDHIA for acute myeloid leukemia, and the RET inhibitor GAVRETO—and contract revenues consisting of royalties and milestone payments from global partners such as Eli Lilly and AstraZeneca. Rigel operates within the specialized hematology and oncology segments, focusing on signaling pathways critical to autoimmune and mid-to-late-stage cancer mechanisms. In the competitive landscape, Rigel contends with mid-cap biotech peers like Dynavax Technologies, MannKind Corporation, and Celldex Therapeutics; however, it distinguishes itself as a lean, commercial-stage specialist that has successfully transitioned from a pure R&D entity to a profitable enterprise with a multi-product portfolio targeting niche orphan indications. The company was founded in 1996 by a distinguished group of Stanford University scientists, including Dr. Garry Nolan and Dr. Thomas Raffin. The current leadership team is led by President and CEO Raul R. Rodriguez, who brings over two decades of experience at Rigel and previous executive roles at Scios and G.D. Searle. He is supported by Executive VP and CFO Dean Schorno, formerly the CFO of 23andMe and Adaptive Biotechnologies, and Chief Medical Officer Dr. Lisa Rojkjaer, an industry veteran with a pedigree from Novartis and Sangamo Therapeutics. Rigel’s governance was recently bolstered by the February 2026 appointment of Michael P. Miller to its Board of Directors. The company maintains a robust institutional investor base, with significant positions held by major financial entities including BlackRock, Vanguard, and BVF Partners, reflecting strong market confidence in its commercial execution and late-stage pipeline assets like R289.